Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares

Rhea-AI Filing Summary

Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Freedman Lori

Role Chief Admin. and Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	43,212	$0.00	--
Tax Withholding	Class A Common Stock	14,411	$3.84	$55K

Holdings After Transaction: Class A Common Stock — 1,038,054 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freedman Lori

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Admin. and Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		43,212(1)	A	$0	1,038,054	D
Class A Common Stock	02/18/2026		F		14,411(1)	D	$3.84	1,023,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.

	/s/ William R. Kolb, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Organogenesis (ORGO) insider Lori Freedman report in this amended Form 4?

Lori Freedman reports updated figures for a performance share award vesting. She shows 43,212 Class A common shares acquired at no cost and 14,411 shares withheld for taxes. The amendment only corrects these share counts from a prior Form 4 filing.

Why was Lori Freedman’s Form 4 for Organogenesis (ORGO) amended?

The Form 4 was amended to correct the number of shares acquired and the number withheld for taxes from a performance share award. The filing states no other changes were made to the original report, focusing solely on these corrected share amounts.

How many Organogenesis (ORGO) shares did Lori Freedman receive from the award?

Lori Freedman received 43,212 shares of Organogenesis Class A common stock from the vesting and settlement of a performance share award. These shares were acquired at a price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.

How many Organogenesis (ORGO) shares were withheld for taxes in this Form 4/A?

The filing reports that 14,411 Class A common shares were disposed of through withholding to satisfy tax obligations tied to the performance share award. This tax-withholding disposition used a transaction price of $3.84 per share for the withheld shares.

What is Lori Freedman’s Organogenesis (ORGO) share ownership after these transactions?

After the award and tax withholding transactions, Lori Freedman’s direct ownership is reported as 1,023,643 shares of Class A common stock. This figure reflects her holdings following both the grant of 43,212 shares and the withholding of 14,411 shares for tax obligations.

Does the Organogenesis (ORGO) Form 4/A indicate any open-market buying or selling?

The Form 4/A shows a grant of 43,212 shares and a tax-withholding disposition of 14,411 shares, not open-market trades. The disposition is specifically described as payment of tax liability by delivering securities, rather than a voluntary buy or sell on the open market.